Journal of Diabetes Investigation: Volume 15, Issue 9 Summary
This issue of the Journal of Diabetes Investigation brings together vital advances in clinical management, early diagnostics, and advanced therapeutics for diabetes. The key research themes focus on practical lifestyle interventions, finding sensitive markers for diabetic kidney complications, and the real-world feasibility of cellular therapies.
Specifically, researchers explore the metabolic benefits of two different intermittent fasting protocols (16:8 vs. 14:10) for patients with obesity and type 2 diabetes. For diabetic kidney disease, new blood biomarkers have been identified that could help trace kidney injury early. Finally, an insightful review on pancreatic islet transplantation highlights how cell-based therapies can drastically improve the life quality of patients with severe type 1 diabetes.
This article was created with the assistance of AI. Although the content is based on original research articles and other academic sources, errors may be present. Please verify the information using the original articles and consult qualified healthcare professionals for medical advice.
Effect of intermittent fasting 16:8 and 14:10 compared with control‐group on weight reduction and metabolic outcomes in obesity with type 2 diabetes patients
Authors: Naparat Sukkriang, Supawan Buranapin
Research Objective: To evaluate and compare the impact of two intermittent fasting (IF) methods (16-hour fast/8-hour eat vs. 14-hour fast/10-hour eat) against a standard diet control group on weight loss and overall metabolic health in individuals with obesity and type 2 diabetes.
Methods: A randomized controlled trial was conducted with 99 participants who completed the study. Over 3 months, participants were assigned to three groups: the IF 16:8 protocol, the IF 14:10 protocol (both followed 3 days a week), or a normal diet control group.
Main Findings: Both intermittent fasting groups showed significant weight loss compared to the control group (which only lost an average of 0.55%). The IF 16:8 group experienced a 4.02% decrease in weight, whereas the IF 14:10 group achieved a 3.15% decrease. The IF 16:8 protocol was significantly more effective for weight loss than the 14:10 protocol. Additionally, both fasting groups experienced notable reductions in fasting blood sugar, HbA1c levels, and improved lipid (cholesterol and fat) profiles compared to controls.
Clinical Significance: Practicing intermittent fasting (either 16:8 or 14:10) just 3 days a week is an accessible and highly effective therapeutic strategy to manage weight, improve blood sugar control, and lower cardiovascular risk in obese type 2 diabetes patients.
- Fasting for 14 or 16 hours on three selected days a week can help you lose weight and manage diabetes more effectively.
- Fasting for 16 hours (16:8) appears to deliver better weight loss results than the 14-hour fast (14:10).
- Both fasting approaches helped improve cholesterol levels and long-term blood sugar controls (HbA1c).
https://doi.org/10.1111/jdi.14186
Relationship between circulating thrombospondin‐1 messenger ribonucleic acid and microribonucleic acid‐194 levels in Chinese patients with type 2 diabetic kidney disease
Authors: Ning Ma, Weiwei Liu, Ning Xu, Dong Yin, Ping Zheng, Guofeng Wang, Yuan Hui, Jiping Zhang, Guanjun Han, Chuanhui Yang, Yan Lu, Xingbo Cheng
Research Objective: To investigate how the levels of certain genetic messengers in the blood (specifically circulating TSP-1 mRNA and miR-194) relate to the presence and severity of diabetic kidney disease (DKD).
Methods: This study analyzed 167 hospitalized patients with type 2 diabetes (divided into three groups based on urinary microalbumin, which indicates kidney function decline) and 163 healthy control subjects. Real-time laboratory analysis was used to measure circulating TSP-1 mRNA and miR-194.
Main Findings: Both markers (TSP-1 mRNA and miR-194) were significantly elevated in type 2 diabetes patients compared to healthy controls. TSP-1 mRNA levels climbed in step with rising levels of albumin in the urine. Statistical analyses showed that TSP-1 mRNA strongly correlated with clinical measures of kidney function (cystatin-c and microalbumin/creatinine ratio). Interestingly, miR-194 showed distinct variations across different stages of kidney damage, marking it as a potentially valuable screening molecule.
Clinical Significance: These molecular markers could act as early, non-invasive blood indicators to assess the presence and severity of kidney damage in diabetes patients, allowing doctors to detect complications before severe damage occurs.
- Diabetic kidney disease is a common complication that requires early detection.
- Scientists have found specific molecules (TSP-1 mRNA and miR-194) in the blood that correlate with early kidney strain.
- In the future, simple blood tests tracking these molecules may help doctors monitor your kidney health more accurately without relying solely on standard urine samples.
https://doi.org/10.1111/jdi.14252
Islet transplantation in Korea
Authors: Joonyub Lee, Kun‐Ho Yoon
Research Objective: To review the clinical implementation, success, and challenges of pancreatic islet transplantation as a cure-oriented treatment for severe Type 1 Diabetes in South Korea.
Methods: This review reports on islet transplantation outcomes performed at a key clinical center in Korea since 2013, highlighting two notable cases of allogenic islet transplantations.
Main Findings: Of the two patients who received transplantations, one achieved near-total insulin independence. The second patient, despite not reaching total insulin independence, had a dramatic reduction in life-threatening episodes of hypoglycemia (severe low blood sugar). These cases show that replacing lost islet cells is highly protective, even when complete insulin-free status is not fully maintained.
Clinical Significance: Islet transplantation represents an invaluable therapy to restore biological glucose control in patients with Type 1 Diabetes who suffer from unstable blood sugar levels and frequent, dangerous low-sugar episodes.
- For type 1 diabetes, daily insulin injections do not always prevent sudden, dangerous blood sugar swings.
- Islet transplantation is a procedure that transplants healthy, insulin-producing donor cells into the recipient's body.
- This treatment can help some patients stop taking insulin entirely and highly reduces dangerous, unexpected drops in blood sugar.
https://doi.org/10.1111/jdi.14264
